Log in

NASDAQ:AXSM - Axsome Therapeutics Stock Price, Forecast & News

$91.13
-1.46 (-1.58 %)
(As of 02/23/2020 04:00 PM ET)
Today's Range
$90.00
Now: $91.13
$92.39
50-Day Range
$85.20
MA: $90.20
$96.31
52-Week Range
$7.64
Now: $91.13
$109.94
Volume440,338 shs
Average Volume567,809 shs
Market Capitalization$3.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.43
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.03 per share
Price / Book3,037.67

Profitability

Net Income$-30,970,000.00

Miscellaneous

Employees29
Market Cap$3.14 billion
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.


Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics Inc (NASDAQ:AXSM) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.15. View Axsome Therapeutics' Earnings History.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Axsome Therapeutics.

What price target have analysts set for AXSM?

10 brokers have issued 1-year price targets for Axsome Therapeutics' shares. Their forecasts range from $25.00 to $200.00. On average, they anticipate Axsome Therapeutics' share price to reach $99.80 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.

What is the consensus analysts' recommendation for Axsome Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.

Has Axsome Therapeutics been receiving favorable news coverage?

Media stories about AXSM stock have trended somewhat negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Axsome Therapeutics earned a news impact score of -1.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Axsome Therapeutics.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,990,000 shares, a decline of 20.7% from the January 15th total of 5,030,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is presently 3.0 days. Currently, 13.9% of the shares of the stock are short sold. View Axsome Therapeutics' Current Options Chain.

Who are some of Axsome Therapeutics' key competitors?

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), NVIDIA (NVDA), Alibaba Group (BABA), Sarepta Therapeutics (SRPT), Viking Therapeutics (VKTX), Netflix (NFLX), AbbVie (ABBV) and AT&T (T).

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:
  • Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)
  • Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)
  • Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)
  • Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)
  • Joseph Debrah-Afful, Director of Fin.

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Alethea Capital Management LLC (2.90%), Iridian Asset Management LLC CT (1.90%), State Street Corp (1.82%), Farallon Capital Management LLC (1.28%), Geode Capital Management LLC (1.07%) and RA Capital Management L.P. (1.07%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics.

Which major investors are selling Axsome Therapeutics stock?

AXSM stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Alethea Capital Management LLC, RA Capital Management L.P., State Street Corp, Schonfeld Strategic Advisors LLC, EAM Investors LLC, Royce & Associates LP and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Axsome Therapeutics.

Which major investors are buying Axsome Therapeutics stock?

AXSM stock was purchased by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, FMR LLC, Driehaus Capital Management LLC, Goldman Sachs Group Inc., Pictet Asset Management Ltd., Renaissance Technologies LLC, Farallon Capital Management LLC and New York State Common Retirement Fund. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad and Nick Pizzie. View Insider Buying and Selling for Axsome Therapeutics.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $91.13.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $3.14 billion. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.View Additional Information About Axsome Therapeutics.

What is Axsome Therapeutics' official website?

The official website for Axsome Therapeutics is http://axsome.com/.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.


MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel